Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Alliqua, Inc. (OTC: ALQA).

Full DD Report for ALQA

Recent News from (OTC: ALQA)

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Alliqua Biomedical, Inc. In The District Of Delaware
NEW YORK , March 13, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for The District  of Delaware , Case No. 1:18-cv-00301, on behalf of shareholders of Alliqua BioMedical, I...
Source: PR Newswire
Date: March, 13 2018 17:32
Midday Gainers / Losers (3/2/2018)
Gainers: ZSAN +32% . VEC +30% . QCP +25% . AVGR +23% . NKTR +22% . SGYP +21% . XON +19% . ALQA +18% . APEI +18% . TTOO +18% . More news on: Zosano Pharma, Vectrus, Quality Care Properties, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 02 2018 12:40
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Alliqua BioMedical, Inc. - ALQA
NEW YORK , Feb. 1, 2018 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York City , is investigating Alliqua BioMedical, Inc. ("Alliqua" or the "Comp...
Source: PR Newswire
Date: February, 01 2018 17:47
Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliqua BioMedical, Inc. (NASDAQ:ALQA), Donegal Group, Inc. (NASDAQ:DGICA...
Source: GlobeNewswire
Date: January, 31 2018 07:40
Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback
Analysis of top Seeking Alpha coverage: Aradigm Today we will discuss the much-anticipated FDA briefing documents for Aradaigm’s ( ARDM ) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11 th . Following the release of the docu...
Source: SeekingAlpha
Date: January, 10 2018 01:14
Wired News - Alliqua BioMedical Enters into Purchase Agreement with Celularity; Agrees to Sell its Advanced Biologic Wound Care Business
LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free research report on Alliqua BioMedical, Inc. (NASDAQ: ALQA ) ("Alliqua"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/re...
Source: ACCESSWIRE IA
Date: January, 09 2018 07:30
Premarket Losers as of 9:05 am
AXON -48%  on announcing negative results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies. More news on: Axovant Sciences, Micro Focus International plc ADR, CRISPR Therapeutics, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: January, 08 2018 09:14
Alliqua BioMedical, Inc. Announces Definitive Asset Purchase Agreement with Celularity, Inc.
YARDLEY, Pa., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) (“Alliqua or the “Company”), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced a definitive agreement with Celularity, Inc. (...
Source: GlobeNewswire
Date: January, 05 2018 16:30
Wired News - Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology
Stock Monitor: Alliqua BioMedical Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 07, 2017 / Active-Investors issued a free report on Shire PLC (NASDAQ: SHPG ), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=SHPG as the ...
Source: ACCESSWIRE IA
Date: December, 07 2017 07:10
Alliqua BioMedical's (ALQA) CEO David Johnson on Q3 2017 Results - Earnings Call Transcript
Alliqua BioMedical, Inc. (ALQA) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives David Johnson - Chief Executive Officer Brad Barton - Chief Operating Officer Brian Posner - Chief Financial Officer Nino Pionati - Chief Strategy and Marketing Officer An...
Source: SeekingAlpha
Date: November, 09 2017 14:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-192.302.262.322.13120,567
2018-04-182.392.322.392.27121,212
2018-04-172.302.382.402.2817,084
2018-04-162.282.30992.36722.24130,564
2018-04-152.202.27042.292.189823,673

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About Alliqua, Inc. (OTC: ALQA)

Logo for Alliqua, Inc. (OTC: ALQA)

Alliqua, Inc., a biomedical products company, through its subsidiaries, focuses on the development and manufacture of proprietary technologies in the fields of drug delivery, advanced wound care, and liver health preservation. The company intends to develop, manufacture, and market active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform. It also manufactures custom hydrogels that are used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. In addition, Alliqua offers HepaMate, an extracorporeal cell based bioartificial liver system to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the severe forms of liver failure.

 

 

 

Current Management

  • David Johnson / CEO
  • Brian M. Posner / CFO
  • Steven Berger / VP, Ops.
  • Jerome B. Zeldis / Chairman
  • Joseph Leone /
  • Kenneth Londoner /
  • Kenneth Pearsen /
  • Jeffrey Sklar /
  • David Stefansky /

Current Share Structure

  • Market Cap: $9,771,016 - 03/20/2018
  • Issue and Outstanding: 4,985,212 - 03/01/2018

 


Recent Filings from (OTC: ALQA)

Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 04 2018
Official notification of matters relating to a merger or acquisition
Filing Type: DEFM14AFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Proxy soliciting materials. Revised preliminary material
Filing Type: PRER14AFiling Source: edgar
Filing Date: March, 09 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 02 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 09 2018
Preliminary proxy statement relating to a merger or acquisition
Filing Type: PREM14AFiling Source: edgar
Filing Date: January, 29 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: January, 05 2018

 

 


Daily Technical Chart for (OTC: ALQA)

Daily Technical Chart for (OTC: ALQA)


Stay tuned for daily updates and more on (OTC: ALQA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ALQA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALQA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ALQA and does not buy, sell, or trade any shares of ALQA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us